Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Fri, Sep 20, 2024
[Archive]
Volume 13 - Covid 19 Supplement 2
Caspian J Intern Med 2022, 13 - Covid 19 Supplement 2: 199-203 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Martsevich S Y, Lukina Y V, Kutishenko N P, Guseynova E T. Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure. Caspian J Intern Med 2022; 13 :199-203
URL: http://caspjim.com/article-1-2689-en.html
URL: http://caspjim.com/article-1-2689-en.html
Department of Preventive Pharmacotherapy, National Medical Research Center for Therapy and Preventive Medicine, Petroverigsky per. 10, Moscow, Russia , e.guseinova@mail.ru
Abstract: (2208 Views)
Background: To assess the influence of the COVID-19 (Coronavirus Disease 2019) pandemic on treatment adherence by patients with CHF (Chronic heart failure) and to determine the factors associated with changing adherence during home-isolation.
Methods: The survey was conducted in patients participating in the COMPLIANCE study (ClinicalTrials.gov. NCT04262583). Thirty-one patients, included into the COMPLIANCE study before March 1, 2020, were interviewed through phone calls. A modified adherence scale of the National Society for Evidence-Based Pharmacotherapy was used, which permits to assess overall adherence, adherence to particular drugs and the main causes for non-adherence.
Results: In the whole group of patients, only a tendency to reduced overall adherence was registered during the COVID-19 pandemic (р=0,256). Significant differences in the rate of adherence deterioration were revealed for angiotensin-converting enzyme (ACE) inhibitors (p=0.031) and for statins (p=0.002). The reasons for non-adherence were lack of opportunity to contact with physician, inability to perform investigations necessary for correcting prescribed pharmacotherapy, and side effects.
Conclusion: A tendency to deterioration of adherence to prescribed pharmacotherapy was revealed during the COVID-19 pandemic. A significant decline in adherence was registered to ACE-inhibitors and statins.
Methods: The survey was conducted in patients participating in the COMPLIANCE study (ClinicalTrials.gov. NCT04262583). Thirty-one patients, included into the COMPLIANCE study before March 1, 2020, were interviewed through phone calls. A modified adherence scale of the National Society for Evidence-Based Pharmacotherapy was used, which permits to assess overall adherence, adherence to particular drugs and the main causes for non-adherence.
Results: In the whole group of patients, only a tendency to reduced overall adherence was registered during the COVID-19 pandemic (р=0,256). Significant differences in the rate of adherence deterioration were revealed for angiotensin-converting enzyme (ACE) inhibitors (p=0.031) and for statins (p=0.002). The reasons for non-adherence were lack of opportunity to contact with physician, inability to perform investigations necessary for correcting prescribed pharmacotherapy, and side effects.
Conclusion: A tendency to deterioration of adherence to prescribed pharmacotherapy was revealed during the COVID-19 pandemic. A significant decline in adherence was registered to ACE-inhibitors and statins.
Keywords: adherence to treatment, period of home-isolation, COVID-19, chronic heart failure, factors of non- adherence
Type of Study: Original Article |
Subject:
Cardiology
Received: 2021/01/4 | Accepted: 2021/09/11 | Published: 2022/04/6
Received: 2021/01/4 | Accepted: 2021/09/11 | Published: 2022/04/6
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
